Cel-Sci (NYSEAMERICAN:CVM) Trading 10% Higher – Here’s What Happened

Cel-Sci Corporation (NYSEAMERICAN:CVM) traded up 10% on Friday . The stock traded as high as $1.5599 and last traded at $1.43. 1,114,174 shares traded hands during mid-day trading, an increase of 59% from the average session volume of 700,046 shares. The stock had previously closed at $1.30.

Cel-Sci Stock Performance

The firm has a market cap of $12.14 million, a PE ratio of -0.15 and a beta of 0.70. The firm has a 50-day moving average price of $3.29 and a two-hundred day moving average price of $4.92. The company has a quick ratio of 1.35, a current ratio of 1.39 and a debt-to-equity ratio of 0.45.

Cel-Sci (NYSEAMERICAN:CVM) last released its earnings results on Friday, May 15th. The company reported ($0.67) earnings per share for the quarter.

Hedge Funds Weigh In On Cel-Sci

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its position in shares of Cel-Sci by 133.0% in the first quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock valued at $115,000 after acquiring an additional 20,484 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Cel-Sci in the fourth quarter valued at approximately $66,000. State Street Corp lifted its position in shares of Cel-Sci by 9.9% in the fourth quarter. State Street Corp now owns 25,570 shares of the company’s stock valued at $134,000 after acquiring an additional 2,300 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Cel-Sci in the fourth quarter valued at approximately $83,000. Finally, HRT Financial LP purchased a new position in shares of Cel-Sci in the fourth quarter valued at approximately $60,000. Hedge funds and other institutional investors own 12.08% of the company’s stock.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.